Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

 
• By Sukaina Virji

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Inchworms
Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock

More from R&D

More from Scrip